CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −12,344 | $49.20 | $607K | 630,196 |
| 2026-04-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −2,656 | $49.92 | $133K | 627,540 |
| 2026-04-01 | Sloan Sheldon Chief Medical Officer | Option exercise 10b5-1 | +7,958 | $21.66 | $172K | 7,958 |
| 2026-04-01 | Sloan Sheldon Chief Medical Officer | Sale 10b5-1 | −7,958 | $50.00 | $398K | 0 |
| 2026-04-01 | Sloan Sheldon Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,958 | 87,542 | ||
| 2026-03-03 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +2,500 | $14.50 | $36K | 100,494 |
| 2026-03-03 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −2,300 | $40.56 | $93K | 98,194 |
| 2026-03-03 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −200 | $41.66 | $8K | 97,994 |
| 2026-03-03 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,500 | 402,357 | ||
| 2026-03-02 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −5,900 | $41.73 | $246K | 651,640 |
| 2026-03-02 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −9,100 | $42.49 | $387K | 642,540 |
| 2026-02-02 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −957 | $31.82 | $30K | 671,583 |
| 2026-02-02 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −14,043 | $32.87 | $462K | 657,540 |
| 2026-01-21 | HENDERSON MICHAEL THOMAS Director | Other acquisition | +63,227 | 168,606 | ||
| 2026-01-09 | Burrows Scott L Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2026-01-09 | Turtle Cameron Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +528,000 | 528,000 | ||
| 2026-01-09 | Sloan Sheldon Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2026-01-09 | King-Jones Heidy See Remarks | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2026-01-02 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −12,709 | $30.47 | $387K | 674,198 |
| 2026-01-02 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −2,191 | $31.79 | $70K | 672,007 |
Page 7 of 11 · 213 trades